Heterogeneously expressed BMCA at the intra-tumor level can lead to preferential targeting of cells with high BCMA while sparing those with low/zero BCMA expression, resulting in the outgrowth of the latter clones33,34,47. The gene discussed is TNFRSF17; the disease is neoplasm.